Cancer R&D 2024 has wrapped up successfully. We’re grateful for your interest and interaction with Alfa Cytology. We’re eager to continue providing our expertise in cancer drug development. Let’s look back on these memorable moments!
Learn More
At Alfa Cytology, we offer a comprehensive range of cancer diagnostic development services to support researchers and pharmaceutical companies in their pursuit of effective cancer diagnostics.
Early detection and diagnosis of breast cancer (BC) is the key to improving curative effects. The diagnosis of BC mainly relies on clinical examination, imaging examination, and needle biopsy. Imaging examination is an important part of early detection of BC and assessment of disease severity after diagnosis, but it also has certain limitations. Breast imaging diagnosis is difficult, and it is difficult to train professional imaging diagnostic personnel, which makes breast AI imaging diagnosis gradually occupy a dominant position. Noninvasive diagnostic biomarkers are currently the best method for BC screening, early diagnosis, or prognosis. Biomarkers detected from body fluids such as blood (serum/plasma), urine, saliva, nipple aspirates, tears, and feces can detect early BC with high precision in a minimally invasive manner.
Fig.1 Ultrasound appearance of dense breasts. (Lee SH, et al., 2022)
Alfa Cytology has extensive experience in BC AI diagnosis and biomarker development. We are committed to helping customers diagnose BC with high precision and successfully develop BC diagnostic biomarkers through customized services, powerful platforms, powerful analysis, and cross-platform collaboration. Our services include,
| Services | Description |
|---|---|
| miRNA biomarkers for breast cancer diagnostics | The expression of miRNA can regulate oncogenes or tumor suppressor genes. Therefore, miRNAs can be used as reliable biomarkers for early detection, prognosis, monitoring of treatment response, and identification of drug resistance mechanisms in BC. |
| Protein biomarkers for breast cancer diagnostics | The proteome is very dynamic, changing dramatically in response to biological signals, environmental conditions, and other external stimuli. Given this critical role, this protein could serve as an important biomarker for BC. |
| Microbiota biomarkers for breast cancer diagnostics | As an important part of the body, the microbiota has recently been recognized as an important mediator of tumor susceptibility and disease progression. The mammary gland and gut microbiota are related to the occurrence and development of BC. |
| ctDNA biomarkers for breast cancer diagnostics | ctDNA is a class of liquid biopsy biomarkers that can be detected in the blood of cancer patients even in the early stages of the disease. |
Alfa Cytology is a leading CRO company with rich experience in BC diagnostic development, advanced technology, and a professional team. If you are interested in learning more about our BC diagnostic development services, please feel free to contact us. Our professional and patient staff will get in touch with you as soon as possible.
Reference